TYMS and non-small cell lung carcinoma: The Samsung Medical Center (Seoul, Korea) is currently enrolling patients in a phase 2 study evaluating the predictive value of TS expression in advanced NSCLC treated with pemetrexed/cisplatin versus gemcitabine/cisplatin (ClinicalTrials.gov Identifier: NCT01401192).